Reading the phase 2 write-up next to the injectable trials, and the comparison people keep making does not survive putting the two protocols side by side.
So the question, as narrowly as I can put it: whether a non-peptide oral agonist can match injectable exposure in practice, or whether the convenience is bought with a lower ceiling.
If the honest answer is that nobody knows, that is a useful answer and I would rather have it.
Short answer first, then the reasoning. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.
PharmD_Rodriguez said:Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then…
No disagreement with PharmD_Rodriguez. One condition attached. Orforglipron is a small molecule rather than a peptide, which is the whole point: no SNAC absorption enhancer, no fasting window, no cold chain, and oral bioavailability in the tens of percent instead of around one. Phase 2 put it near 14.7% weight loss at 36 weeks on the top dose with a side-effect profile that looks like the injectables.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsBenResearch_OR said:Reading the phase 2 write-up next to the injectable trials, and the comparison people keep making does not survive putting the two protocols side by…
Same experience, arrived at from the opposite direction.
Adding the clinical framing, because it changes how the question reads. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.